MassMutual Private Wealth & Trust FSB Buys 1,653 Shares of Stryker Co. (NYSE:SYK)

MassMutual Private Wealth & Trust FSB grew its stake in Stryker Co. (NYSE:SYK - Free Report) by 2.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,294 shares of the medical technology company's stock after buying an additional 1,653 shares during the quarter. MassMutual Private Wealth & Trust FSB's holdings in Stryker were worth $25,795,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Capital & Planning LLC boosted its holdings in shares of Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after purchasing an additional 29 shares during the period. Brighton Jones LLC increased its stake in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after acquiring an additional 609 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in shares of Stryker by 47.6% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,696 shares of the medical technology company's stock valued at $971,000 after purchasing an additional 870 shares during the period. Pacer Advisors Inc. increased its position in shares of Stryker by 21.8% in the fourth quarter. Pacer Advisors Inc. now owns 31,925 shares of the medical technology company's stock valued at $11,495,000 after buying an additional 5,704 shares in the last quarter. Finally, Foundations Investment Advisors LLC grew its holdings in Stryker by 12.2% in the 4th quarter. Foundations Investment Advisors LLC now owns 1,967 shares of the medical technology company's stock valued at $708,000 after buying an additional 214 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Shares of Stryker stock traded up $0.51 during trading on Friday, reaching $382.86. The company's stock had a trading volume of 1,993,145 shares, compared to its average volume of 1,342,850. The business's fifty day moving average price is $368.77 and its 200-day moving average price is $376.22. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The firm has a market cap of $146.13 billion, a price-to-earnings ratio of 49.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the firm posted $2.50 EPS. The business's revenue was up 11.9% compared to the same quarter last year. As a group, equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's payout ratio is currently 45.41%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Roth Mkm lifted their price target on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Citigroup reissued a "buy" rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Sanford C. Bernstein set a $450.00 price objective on Stryker in a research note on Monday, May 5th. BTIG Research set a $403.00 target price on shares of Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Finally, Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.